MR GENTLE

The Multicenter Randomized trial of Ghrelin in anterior circulation ischemic stroke treated with endovascular thrombectomy (MR GENTLE) is a randomized phase 2 trial with a PROBE design. The primary objective of this study is to assess the effect of intravenous acyl-ghrelin – as a potential neuroprotective drug – on the severity of the neurological deficit at seven days after symptom onset in patients with acute ischemic stroke caused by large vessel occlusion of the anterior circulation and treated with EVT. Inclusion started in November 2024 and is expected to end in Q1/Q2 2026. The trial is registered with EU trial number: 2024-515705-26-00.